Clinical Trial Supply & Logistics for Pharmaceutical Market by Phase, Sector, Therapeutic Area

Description

List of Tables

[195 Pages Report] The Clinical Trial Supply & Logistics for Pharmaceutical Market size was estimated at USD 22.73 billion in 2023 and expected to reach USD 24.48 billion in 2024, at a CAGR 7.75% to reach USD 38.34 billion by 2030.

The clinical trial supply chain is a critical aspect of the pharmaceutical industry, as it involves the storage, distribution, and monitoring of investigational medicinal products (IMPs) used in clinical studies. Clinical trial logistics primarily aim to ensure that the essential resources are available at the right time, place, and under optimal conditions to maintain quality throughout the trial process. Clinical trial supply & logistics plays a vital role in the overall success of drug development programs by directly impacting cost management, risk mitigation, efficiency improvement, and patient safety. Some major trends contributing to this industry growth include the globalization of clinical trials, the adoption of technology-driven solutions, and the outsourcing of non-core functions within pharmaceutical companies. The growth of the clinical trial supply & logistics (CTSL) market has been significantly influenced by the increasing Research and Development (R&D) expenditure in the pharmaceutical sector. Pharmaceutical R&D is vital in developing innovative drugs and therapies that improve healthcare outcomes worldwide. The continuous expansion in R&D investments has propelled advancements in clinical trial processes, leading to robust growth in the clinical trial supply & logistics industry. The pharmaceutical industry has faced significant challenges due to the escalating drug development costs and clinical trials. These increased expenses have substantially impacted various aspects of the industry, leading to reduced investment by pharmaceutical companies in their clinical trial supply chain management systems. In recent years, the pharmaceutical industry substantially increased in outsourcing clinical trial activities to contract research organizations (CROs) and other third-party service providers. Multiple factors drive this trend, including the need for cost reduction, access to specialized expertise, and the demand for faster drug development processes, which has significantly supplemented growth in the clinical trial supply chain and logistics services.

KEY MARKET STATISTICS
Base Year [2023]	USD 22.73 billion
Estimated Year [2024]	USD 24.48 billion
Forecast Year [2030]	USD 38.34 billion
CAGR (%)	7.75%

Phase: Rising inclination toward Phase III trials owing to the need for exponential utility of clinical trial supply & logistics

In BA/BE studies, the focus is on efficient supply chain solutions that support the comparison of a test drug against a reference, highlighting the necessity for timely availability of materials, compliance, and regulatory adherence. Phase I trials, targeting a small cohort for safety and pharmacokinetics evaluations, demand highly flexible and responsive supply solutions to accommodate the dynamic nature of early-stage research. Phase II expands to assess drug efficacy and side effects in larger groups, necessitating advanced forecasting, inventory management, and distribution strategies to address the complexities of multiple trial sites while ensuring compliance. The scale increases further in Phase III, where the efficacy and monitoring of adverse reactions require scalable, reliable supply and global logistics expertise to manage trials across numerous sites and countries efficiently. Phase IV focuses on the post-approval monitoring of a drug's long-term effectiveness, necessitating a shift towards wider commercial distribution channels yet maintaining a focus on regulatory compliance and patient safety.

Therapeutic Area: Exponential utility of clinical trial supply & logistics to cater to the ever-growing oncology R&D activities

The clinical trial supply and logistics sector for pharmaceuticals is crucial in advancing treatments across various therapeutic areas. For blood disorders such as anemia, hemophilia, and sickle cell disease, the focus is on the specialized handling of biological materials, emphasizing cold chain logistics to uphold the integrity of trial supplies. The segment covering digestive system diseases, including inflammatory bowel and gastrointestinal cancers, demands rigorous adherence to regulatory standards for managing biologics and personalized medicines, frequently requiring innovative packaging and temperature-controlled transport solutions. In the realm of infectious and immune system diseases, spanning from HIV/AIDS to autoimmune disorders such as rheumatoid arthritis. Trials targeting neurological and mental disorders, such as Alzheimer's and depression, necessitate detailed planning for the distribution of sensitive psychoactive compounds, often calling for specialized courier services. The oncology segment, significant due to the growing number of cancer research studies, entails strict risk management and safety protocols for handling cytotoxic agents and biologics, underlining the need for secure delivery systems in line with international standards.

Regional Insights

Americas has endured a significant position in the pharmaceutical market's clinical trial supply & logistics due to the adoption of technologically advanced products, well-established regulatory agencies, and considerable contract research organizations. The United States is increasingly focusing on generics and biologics, both cost-effective alternatives to traditional pharmaceuticals. The market has witnessed an increase in business growth with rising demand for generic prescription drugs that the FDA has approved to be the equivalent of a brand-name drug in dosage, safety, strength, quality, performance, and intended use. Asia-Pacific's expanding technology sector and enhancement in the pharmaceutical services in emerging countries such as China, Korea, and India create several growth opportunities for supply chain management solutions. In contrast, countries such as Australia, Japan, and Singapore represent the developed healthcare systems in the region. EMEA clinical trial supply & logistics for the pharmaceutical market has focused on the re-oriented healthcare and pharmaceutical systems to ensure efficient service delivery. The European region represents the developed market, closely following the developed market's technological and healthcare development trends. The European Union (EU) plays a significant role in the pharmaceutical industry and is a substantial trader in pharmaceuticals and medicinal products. Manufacturing and distribution have also become increasingly globalized, with the maintenance of supply & logistics integrity becoming a high priority for ensuring the safety and quality of drugs and devices, increasing demand for next-generation clinical trial supply & logistics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Clinical Trial Supply & Logistics for Pharmaceutical Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Clinical Trial Supply & Logistics for Pharmaceutical Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Clinical Trial Supply & Logistics for Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include Almac Group, AmerisourceBergen Corporation, Bilcare Limited, Biocair International Limited, Catalent, Inc., Clinigen Group PLC, DHL International GmbH by Deutsche Post AG, Eurofins Scientific SE, FedEx Corporation, ICON PLC, Infosys Limited, KLIFO A/S, Lonza Group, Marken, Movianto, N-Side, Parexel International Corporation, PCI Pharma Services, Seveillar Clinical Trial Supplies Pvt. Ltd., SIRO Clinpharm Private Limited, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Clinical Trial Supply & Logistics for Pharmaceutical Market to forecast the revenues and analyze trends in each of the following sub-markets:

Phase
- BA/BE Studies
- Phase I
- Phase II
- Phase III
- Phase IV

Sector
- Clinical Trial Logistics and Distributions
- Clinical Trial Manufacturing Services
- Clinical Trial Supply Chain Management

Therapeutic Area
- Blood Disorders
- Digestive System Diseases
- Infectious and Immune System Diseases
- Neurological and Mental Disorders
- Oncology

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Clinical Trial Supply & Logistics for Pharmaceutical Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Clinical Trial Supply & Logistics for Pharmaceutical Market?

3. What are the technology trends and regulatory frameworks in the Clinical Trial Supply & Logistics for Pharmaceutical Market?

4. What is the market share of the leading vendors in the Clinical Trial Supply & Logistics for Pharmaceutical Market?

5. Which modes and strategic moves are suitable for entering the Clinical Trial Supply & Logistics for Pharmaceutical Market?

Product Code: MRR-4311CE1A33A9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing R&D Expenditure of Pharmaceutical and Biopharmaceutical Industry
  - 5.1.1.2. Increased Focus on Drug Development
  - 5.1.1.3. Globalization of Clinical Trials and Harmonization of Regulations
- 5.1.2. Restraints
  - 5.1.2.1. Increased Cost of Drug Development and Clinical Trials
- 5.1.3. Opportunities
  - 5.1.3.1. Outsourcing of Clinical Trial Activity
  - 5.1.3.2. Increased Focus on Generics and Biologics
  - 5.1.3.3. Regulatory Approvals in Emerging Markets
- 5.1.4. Challenges
  - 5.1.4.1. Logistics Challenges Across Nations
5.2. Market Segmentation Analysis
- 5.2.1. Phase: Rising inclination toward Phase III trials owing to the need for exponential utility of clinical trial supply & logistics
- 5.2.2. Therapeutic Area: Exponential utility of clinical trial supply & logistics to cater to the ever-growing oncology R&D activities
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Clinical Trial Supply & Logistics for Pharmaceutical Market, by Phase

6.1. Introduction
6.2. BA/BE Studies
6.3. Phase I
6.4. Phase II
6.5. Phase III
6.6. Phase IV

7. Clinical Trial Supply & Logistics for Pharmaceutical Market, by Sector

7.1. Introduction
7.2. Clinical Trial Logistics and Distributions
7.3. Clinical Trial Manufacturing Services
7.4. Clinical Trial Supply Chain Management

8. Clinical Trial Supply & Logistics for Pharmaceutical Market, by Therapeutic Area

8.1. Introduction
8.2. Blood Disorders
8.3. Digestive System Diseases
8.4. Infectious and Immune System Diseases
8.5. Neurological and Mental Disorders
8.6. Oncology

9. Americas Clinical Trial Supply & Logistics for Pharmaceutical Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Clinical Trial Supply & Logistics for Pharmaceutical Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Clinical Trial Supply & Logistics for Pharmaceutical Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Ariceum Therapeutics and Eurofins CDMO Sign a Pharmaceutical Multi-Project Agreement
- 12.3.2. Catalent Completes Expansion of Singapore Clinical Supply Facility for Increased Temperature-Controlled Capabilities
- 12.3.3. Parexel Opens Clinical Trial Supplies and Logistics Depot in Suzhou, China

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio